Minimal change disease: a dysregulation of the podocyte CD80–CTLA-4 axis?

Pediatric Nephrology

Volumn 29, Issue 12, 2014, Pages 2333-2340

  Cara Fuentes, Gabriel ^a   Wasserfall, Clive H ^b   Wang, Heiman ^a   Johnson, Richard J ^c   Garin, Eduardo H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

CD80; CTLA 4; Minimal Change Disease; Podocyte

Indexed keywords

B7 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPOTHESIS; MINIMAL CHANGE DISEASE; NEPHROTIC SYNDROME; PODOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; SCHOOL CHILD; STEROID THERAPY; URINARY EXCRETION; YOUNG ADULT;

EID: 84920973407     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2874-8     Document Type: Article

References (18)

1. Feehally J, Floege J, Johnson RJ (2007) Comprehensive clinical nephrology, 3rd edn. Mosby Elsevier, Philadephia, pp 209–216
2. Alwadhi RK, Mathew JL, Rath B (2004) Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health 40:28–32
3. Ponticelli C, Glassock RJ (2010) Treatment of primary glomerulonephritis, 2nd edn. Oxford University Press, New York
4. Barisoni L, Schnaper HW, Kopp JB (2007) A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2:529–542
5. Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ (2010) Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78:296–302
6. Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20:260–266
7. Ishimoto T, Shimada M, Gabriela G, Kosugi T, Sato W, Lee PY, Lanaspa MA, Rivard C, Maruyama S, Garin EH, Johnson RJ (2013) Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol Dial Transplant 28:1439–1446
8. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271–275
9. Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH (2011) Minimal change disease: a “Two hit” podocyte immune disorder? Pediatr Nephrol 26:645–649
10. Churg J, Habib R, White RH (1970) Pathology of the nephrotic syndrome in children: a report for the International Study of kidney Disease in Children. Lancet 760:1299–1302
11. [No authors cited] (1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 20:765–771
12. Oaks MK, Hallet KM (2000) Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 164:5015–5018
13. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2:116–126
14. Niemann-Masanek U, Mueller A, Yard BA, Waldherr R, van der Woude FJ (2002) B7–1 (CD80) and B7–2 (CD86) expression in human tubular epithelial cells in vivo and in vitro. Nephron 92:542–556
15. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P (2004) Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113:1390–1397
16. Xia M, Gasser J, Feige U (1999) Dexamethasone enhances CTLA-4 expression during T cell activation. Cell Mol Life Sci 55:1649–1656
17. Spink C, Stege G, Tenbrock K, Harendza S (2013) The CTLA-4 + 49GG genotype is associated with susceptibility for nephrotic kidney diseases. Nephrol Dial Transplant 28:2800–2805
18. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86–94